Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Large Increase in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totaling 674,952 shares, an increase of 51.1% from the March 15th total of 446,652 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 503,039 shares, the days-to-cover ratio is currently 1.3 days.

Insider Buying and Selling at Nautilus Biotechnology

In related news, CEO Sujal M. Patel acquired 25,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were purchased at an average price of $2.61 per share, for a total transaction of $65,250.00. Following the transaction, the chief executive officer owned 10,366,721 shares in the company, valued at $27,057,141.81. This represents a 0.24% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 41.10% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. Garde Capital Inc. bought a new position in shares of Nautilus Biotechnology during the 4th quarter valued at $35,000. Hudson Bay Capital Management LP bought a new stake in Nautilus Biotechnology in the 4th quarter worth $37,000. Virtu Financial LLC grew its holdings in Nautilus Biotechnology by 19.6% in the 4th quarter. Virtu Financial LLC now owns 23,532 shares of the company’s stock worth $46,000 after acquiring an additional 3,849 shares during the last quarter. Captrust Financial Advisors bought a new stake in Nautilus Biotechnology in the 4th quarter worth $66,000. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Nautilus Biotechnology in the 3rd quarter worth $38,000. Institutional investors own 50.71% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on NAUT. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. Guggenheim increased their target price on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a report on Friday, February 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

Nautilus Biotechnology Stock Performance

Shares of NAUT stock traded up $0.19 on Wednesday, hitting $3.25. 275,962 shares of the company’s stock traded hands, compared to its average volume of 434,912. Nautilus Biotechnology has a one year low of $0.62 and a one year high of $4.31. The company’s fifty day simple moving average is $2.80 and its 200 day simple moving average is $2.11. The stock has a market capitalization of $411.32 million, a price-to-earnings ratio of -6.91 and a beta of 1.08.

Nautilus Biotechnology (NASDAQ:NAUT) last released its earnings results on Thursday, February 26th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, sell-side analysts anticipate that Nautilus Biotechnology will post -0.57 earnings per share for the current fiscal year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.